314 related articles for article (PubMed ID: 24524666)
1. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization.
Hicks JK; Swen JJ; Gaedigk A
Curr Drug Metab; 2014 Feb; 15(2):218-32. PubMed ID: 24524666
[TBL] [Abstract][Full Text] [Related]
2. Complexities of CYP2D6 gene analysis and interpretation.
Gaedigk A
Int Rev Psychiatry; 2013 Oct; 25(5):534-53. PubMed ID: 24151800
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM; Raimundo S; Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
[TBL] [Abstract][Full Text] [Related]
4. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
[TBL] [Abstract][Full Text] [Related]
5. How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments.
De Gregori M; Allegri M; De Gregori S; Garbin G; Tinelli C; Regazzi M; Govoni S; Ranzani GN
Curr Drug Metab; 2010 Mar; 11(3):276-82. PubMed ID: 21171195
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
Griese EU; Zanger UM; Brudermanns U; Gaedigk A; Mikus G; Mörike K; Stüven T; Eichelbaum M
Pharmacogenetics; 1998 Feb; 8(1):15-26. PubMed ID: 9511177
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
[TBL] [Abstract][Full Text] [Related]
9. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.
Thuerauf N; Lunkenheimer J
Eur Arch Psychiatry Clin Neurosci; 2006 Aug; 256(5):287-93. PubMed ID: 16783493
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
11. Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing.
Cavallari LH; Van Driest SL; Prows CA; Bishop JR; Limdi NA; Pratt VM; Ramsey LB; Smith DM; Tuteja S; Duong BQ; Hicks JK; Lee JC; Obeng AO; Beitelshees AL; Bell GC; Blake K; Crona DJ; Dressler L; Gregg RA; Hines LJ; Scott SA; Shelton RC; Weitzel KW; Johnson JA; Peterson JF; Empey PE; Skaar TC;
Genet Med; 2019 Oct; 21(10):2255-2263. PubMed ID: 30894703
[TBL] [Abstract][Full Text] [Related]
12. Using population pharmacokinetic analyses of drugs metabolized by CYP2D6 to study the genotype-phenotype translation.
Frederiksen T
Basic Clin Pharmacol Toxicol; 2023 Aug; 133(2):113-123. PubMed ID: 37221697
[TBL] [Abstract][Full Text] [Related]
13. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data.
Gaedigk A; Gotschall RR; Forbes NS; Simon SD; Kearns GL; Leeder JS
Pharmacogenetics; 1999 Dec; 9(6):669-82. PubMed ID: 10634130
[TBL] [Abstract][Full Text] [Related]
14. Prediction of CYP2D6 phenotype from genotype across world populations.
Gaedigk A; Sangkuhl K; Whirl-Carrillo M; Klein T; Leeder JS
Genet Med; 2017 Jan; 19(1):69-76. PubMed ID: 27388693
[TBL] [Abstract][Full Text] [Related]
15. Advancing CYP2D6 Pharmacogenetics through a Pharmacoequity Lens.
Kehinde O; Ramsey LB; Gaedigk A; Oni-Orisan A
Clin Pharmacol Ther; 2023 Jul; 114(1):69-76. PubMed ID: 36924260
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency.
Linder MW; Prough RA; Valdes R
Clin Chem; 1997 Feb; 43(2):254-66. PubMed ID: 9023127
[TBL] [Abstract][Full Text] [Related]
17. Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity.
Dalton R; Lee SB; Claw KG; Prasad B; Phillips BR; Shen DD; Wong LH; Fade M; McDonald MG; Dunham MJ; Fowler DM; Rettie AE; Schuetz E; Thornton TA; Nickerson DA; Gaedigk A; Thummel KE; Woodahl EL
Clin Transl Sci; 2020 Jan; 13(1):147-156. PubMed ID: 31536170
[TBL] [Abstract][Full Text] [Related]
18. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group.
Caudle KE; Sangkuhl K; Whirl-Carrillo M; Swen JJ; Haidar CE; Klein TE; Gammal RS; Relling MV; Scott SA; Hertz DL; Guchelaar HJ; Gaedigk A
Clin Transl Sci; 2020 Jan; 13(1):116-124. PubMed ID: 31647186
[TBL] [Abstract][Full Text] [Related]
19. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
20. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres M; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(10 Suppl):S571-4. PubMed ID: 18957039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
